Schulz, Christian (2021) Advances in Lung Cancer Treatment. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 146 (19). pp. 1283-1286. ISSN 0012-0472, 1439-4413
Full text not available from this repository. (Request a copy)Abstract
Immuno-oncologic monotherapy for NSCLC 5-year survival data from the KEYNOTE-024 trial confirm the sustained efficacy of immuno-oncologic monotherapy in patients with NSCLC with high PD-L1 expression (>= 50%). Dual immunotherapy in combination with chemotherapy as first-line therapy for NSCLC Nivolumab plus impilimumab in combination with 2 cycles of platinum-containing chemotherapy improves survival in NSCLC patients. Novel targets and treatment options Entrectinib and larotrectinib with efficacy in NTRK fusion-positive NSCLC. Selpercatinib and pralsetinib with efficacy in RET fusion-positive NSCLC. Mobocertinib with efficacy in EGFRex20ins mutation of the EGFR gene. Sotorasib with efficacy in kRAS-G12C mutation of NSCLC. National Network Genomic Medicine Lung Cancer (nNGM) The nationwide network nNGM provides NSCLC patients with access to state-of-the-art molecular diagnostics and the latest treatment options.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | POSITIVE SOLID TUMORS; CHEMOTHERAPY; immunotherapy; targeted therapy; National Network Genomic Medicine Lung Cancer |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Zentren des Universitätsklinikums Regensburg > Tumorzentrum e.V. |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Aug 2022 13:13 |
| Last Modified: | 09 Aug 2022 13:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/46243 |
Actions (login required)
 |
View Item |
